---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-341240"
form_type: "8-K"
ticker: "SLN"
cik: "0001479615"
company_name: "Silence Therapeutics plc"
filed_at: "2026-08-10T11:20:14+00:00"
generated_at: "2026-08-10T11:25:06.161699+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Silence Therapeutics Q2 2026 net loss narrows to $12.3M; divesiran Phase 2 dosing complete

## Summary
- Net loss $12.3M ($0.09/share) vs $27.4M ($0.19/share) in Q2 2025; cash $72.1M at June 30, 2026.
- R&D expenses fell to $9.1M from $17.6M YoY, mainly due to zerlasiran Phase 3 readiness completion and lower personnel costs.
- Divesiran Phase 2 SANRECO trial completed patient dosing in 48 phlebotomy-dependent PV patients; EHA 2026 data presented.
- SLN312 (AZD1705) Phase 1 results from AstraZeneca collaboration presented at EAS 2026; favorable safety and dose-dependent lipid reductions.
- Preclinical SLN365 (GPR146) and SLN098 (INHBE) programs on track for potential IND filings in 2027.

## SEC filing metadata
- accession: 0001193125-26-341240
- form_type: 8-K
- ticker: SLN
- cik: 0001479615
- company_name: Silence Therapeutics plc
- filed_at: 2026-08-10T11:20:14+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479615/000119312526341240/0001193125-26-341240-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479615/000119312526341240/d162225d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-341240
- JSON: https://secwatch.observer/filing/0001193125-26-341240.json
- Plain text: https://secwatch.observer/filing/0001193125-26-341240.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.